Yvidually

  • Procedure started
  • Under evaluation
  • CHMP opinion
  • European Commission final decision
Current status
European Commission final decision

Overview

On 19 April 2012, the European Medicines Agency completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Yvidually and associated names. The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Yvidually outweigh its risks, and the marketing authorisation can be granted in all EU Member States as well as Iceland and Norway.

Key facts

About this medicine
Approved name
Yvidually
International non-proprietary name (INN) or common name
  • ethinylestradiol
  • drospirenone
Associated names
Flexyess
About this procedure
Current status
European Commission final decision
Reference number
EMEA/H/A-29/1330
Type
Article 29(4) referrals

This type of referral is triggered when there is a disagreement between Member States regarding a marketing authorisation application being evaluated in a mutual-recognition or decentralised procedure, on the grounds of a potential serious risk to public health.

Key dates and outcomes
CHMP opinion date
19/04/2012
EC decision date
28/09/2012

All documents

European Commission final decision

  • List item

    Questions and answers on Yvidually and associated names (ethinylestradiol / drospirenone, 0.02 mg/3 mg tablets) (PDF/57 KB)

    Adopted

    First published: 20/04/2012
    Last updated: 03/01/2012
    EMA/265750/2012 Rev.1

  • List item

    Yvidually Article 29(4) referral - Annex I (PDF/166.4 KB)


    First published: 03/01/2013
    Last updated: 03/01/2013

  • List item

    Yvidually Article 29(4) referral - Annex II (PDF/130.7 KB)


    First published: 03/01/2013
    Last updated: 03/01/2013

  • List item

    Yvidually Article 29(4) referral - Annex III (PDF/34.79 KB)


    First published: 03/01/2013
    Last updated: 03/01/2013

  • List item

    Yvidually Article 29(4) referral - Annex IV (PDF/37.94 KB)


    First published: 03/01/2013
    Last updated: 03/01/2013

  • List item

    Yvidually Article 29(4) referral - Assessment report (PDF/324.93 KB)

    Adopted

    First published: 03/01/2013
    Last updated: 03/01/2013
    EMA/552336/2012

  • Description of documents published

    Please note that some of the listed documents apply only to certain procedures.

    • Overview - lay-language summary of the stage of the procedure
    • Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
    • Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
    • List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
    • Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
    • List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
    • List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
    • Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
    • Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
    • Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
    • Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
    • Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
    • Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
    • Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
    • Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)

    Note that older documents may have different titles.

    How useful was this page?

    Add your rating